Skip to content
    • Fund your company
      Access capital and expertise to accelerate growth
    • Form your startup
      Turning breakthrough science into durable companies
    • Invest with RA Capital
      Evidence-based investing in healthier futures
    • Work at RA Capital
      Join the teams working to reimagine health
    • Overview
    • Our Advantage
    • Team
    • Portfolio
    • Careers
    • Overview
    • Healthcare Team
    • Healthcare Portfolio
    • Overview
    • Planetary Health Team
    • Planetary Health Portfolio
    • Overview
    • Raven
      Healthcare incubator
    • Blackbird
      Clinical development accelerator
    • TechAtlas
      Knowledge engine
    • Overview
    • Gateway ↗
      Board tools
    • Rapport
      RA Capital insights & opinions
    • RA University ↗
      Free online courses
    • All News
    • RA Capital News
    • In The Media
  • Advocacy
  • Contact
more results result found

Tyra’s Dabogratinib and the FGFR3 Switch That Makes Cells Both Stop and Go

10/27/26
Written by
Peter Kolchinsky
Peter Kolchinsky

Managing Partner

Jake Simson
Jake Simson

Partner

Richard Xie
Richard Xie

Senior Health Economist

  • Privacy Policy
  • Investor Login ↗
  • LinkedIn ↗
© 2026 RA Capital Management, L.P.

This website is for informational purposes only and does not constitute an offer to provide investment advisory or other services by RA Capital Management, L.P. (“RA Capital”). Nothing contained on the website constitutes investment advice, and the views expressed should not be taken as advice to buy, sell, or hold any security or as an endorsement of any security or company. In preparing the information contained in this website, RA Capital has not taken into account the investment needs, objectives, and financial circumstances of any particular investor, and investments and companies referenced may not be suitable for all investors. Any views expressed were prepared based upon information available and believed to be reliable at the time such views were written. RA Capital makes no guarantees as to their accuracy or completeness. All information is subject to change and may quickly become unreliable for various reasons, including changes in market conditions or economic circumstances. By accessing this website, you agree not to copy, reproduce, republish, upload, post, transmit, alter, or distribute, in any way, content or materials from this website in any manner inconsistent with the purposes for which it is offered without the prior written consent of RA Capital.